Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry

Am J Physiol Cell Physiol. 2013 May 15;304(10):C945-53. doi: 10.1152/ajpcell.00346.2012. Epub 2013 Feb 7.

Abstract

Angiotensin-converting enzyme 2 (ACE2) catalyzes conversion of ANG II to ANG-(1-7). The present study uses newly established proteomic approaches and genetic mouse models to examine the contribution of alternative renal peptidases to ACE2-independent formation of ANG-(1-7). In situ and in vitro mass spectrometric characterization showed that substrate concentration and pH control renal ANG II processing. At pH ≥6, ANG-(1-7) formation was significantly reduced in ACE2 knockout (KO) mice. However, at pH <6, formation of ANG-(1-7) in ACE2 KO mice was similar to that in wild-type (WT) mice, suggesting alternative peptidases for renal ANG II processing. Furthermore, the dual prolyl carboxypeptidase (PCP)-prolyl endopeptidase (PEP) inhibitor Z-prolyl-prolinal reduced ANG-(1-7) formation in ACE2 KO mice, while the ACE2 inhibitor MLN-4760 had no effect. Unlike the ACE2 KO mice, ANG-(1-7) formation from ANG II in PEP KO mice was not different from that in WT mice at any tested pH. However, at pH 5, this reaction was significantly reduced in kidneys and urine of PCP-depleted mice. In conclusion, results suggest that ACE2 metabolizes ANG II in the kidney at neutral and basic pH, while PCP catalyzes the same reaction at acidic pH. This is the first report demonstrating that renal ANG-(1-7) formation from ANG II is independent of ACE2. Elucidation of ACE2-independent ANG-(1-7) production pathways may have clinically important implications in patients with metabolic and renal disease.

Keywords: angiotensin-converting enzyme 2; angiotensinase C; mass spectrometry; prolyl endopeptidase; renin-angiotensin system.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin I / urine*
  • Angiotensin II / metabolism
  • Angiotensin II / urine*
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Carboxypeptidases / antagonists & inhibitors
  • Carboxypeptidases / metabolism*
  • Carboxypeptidases / pharmacokinetics
  • Dipeptides / pharmacology
  • Imidazoles / pharmacology
  • Kidney / metabolism
  • Leucine / analogs & derivatives
  • Leucine / pharmacology
  • Male
  • Mice
  • Mice, Knockout
  • Peptide Fragments / urine*
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid
  • Angiotensin-Converting Enzyme Inhibitors
  • Dipeptides
  • Imidazoles
  • Peptide Fragments
  • Angiotensin II
  • N-benzyloxycarbonylprolylprolinal
  • Angiotensin I
  • Carboxypeptidases
  • Peptidyl-Dipeptidase A
  • lysosomal Pro-X carboxypeptidase
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2
  • Leucine
  • angiotensin I (1-7)